Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group Study - Wikidata - wikimedia - TriplyDB

Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group Study

Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group Study

http://www.wikidata.org/entity/Q30411910

about

Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives Critical appraisal of bevacizumab in the treatment of ovarian cancer Patient preferences in advanced or recurrent ovarian cancer.Paclitaxel targets VEGF-mediated angiogenesis in ovarian cancer treatment Bevacizumab in ovarian cancer: A critical review of phase III studies Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer.A cost-utility analysis of NRG Oncology/Gynecologic Oncology Group Protocol 218: incorporating prospectively collected quality-of-life scores in an economic model of treatment of ovarian cancer.Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial.Health-related quality of life in ovarian cancer survivors: Results from the American Cancer Society's Study of Cancer Survivors - I.Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer.Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.New biological treatments for gynecological tumors: focus on angiogenesis.Bevacizumab: a review of its use in advanced cancer.Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) study.Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial.Bevacizumab treatment and quality of life in advanced ovarian cancer.Systematic Review of Cytoreductive Surgery and Bevacizumab-Containing Chemotherapy in Advanced Ovarian Cancer: Focus on Safety.A Systematic Review of Health-Related Quality of Life Reporting in Ovarian Cancer Phase III Clinical Trials: Room to Improve.

P2860

Q26751280-80100630-95A6-4A8B-8473-3FFD37FCF651 Q26830403-B1A5C727-84AD-4D39-BCF5-8DD7168A992E Q27336251-65B61E8F-9ECC-46F2-BB5D-83CD9893D597 Q28073057-DBEAC3DE-364D-415B-A093-4E2CDDF25EEF Q28076188-C50A4203-02BC-41B3-938A-9B45B0185A55 Q33800676-1B10DC1A-9561-4FE2-83C8-52AF66DF5808 Q35883007-795A4FDB-A8A7-48BF-8B2B-7BC48B4DA2E1 Q36680034-C9843A3A-30F9-4B32-A9A1-545544C6BD4A Q37019831-9ED6B220-CB87-4CB9-98CC-99004EC3F4D4 Q37040827-C2EF7B95-0676-432B-8A5A-75E7F16461CC Q38111265-E8451053-3890-4EFB-ADCD-02839BA79067 Q38175506-9AE54AE4-A955-4AC4-B9CF-EB901DDA8A69 Q38260176-5E90A5FE-C453-4205-8F8C-5FAA3CA86D19 Q38661788-DA2A143D-9A1F-424F-AC75-C2DBC89FC9D1 Q38879397-4E230FC9-4800-498B-95E9-5F27D734DB26 Q39388197-2F0D6A4F-0392-4453-876E-0CF4F1A60F48 Q47603079-1E4D3ABF-6776-4FCF-86A6-8B796076031D Q47629735-B6186C89-6F1E-4972-8548-6A4B97DBE76D

P2860

Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group Study

http://www.wikidata.org/entity/Q30411910

description

2012 nî lūn-bûn

@nan

2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Patient reported outcomes of a ...... necologic Oncology Group Study

@ast

Patient reported outcomes of a ...... necologic Oncology Group Study

@en

type

label

Patient reported outcomes of a ...... necologic Oncology Group Study

@ast

Patient reported outcomes of a ...... necologic Oncology Group Study

@en

prefLabel

Patient reported outcomes of a ...... necologic Oncology Group Study

@ast

Patient reported outcomes of a ...... necologic Oncology Group Study

@en

P1433

Q30411910-F6DFFC5A-0897-4930-92AB-4F34233650C9

P1476

Q30411910-9A07AA86-DBF6-4096-A18B-139B57D339C9

P2093

Q30411910-149E9FFB-4496-4E69-A19B-0DDFC1A2F62F

Q30411910-15BDCC1C-665D-41A3-A7EA-00E5F44167B7

Q30411910-400F5BD4-250C-410A-85CC-9945EEBDA17E

Q30411910-4CA59537-6899-416F-B470-46B944190514

Q30411910-5A786823-6BD6-44F5-B06D-0A5CBAE733AC

Q30411910-6996A9C3-1909-49F2-8A52-F60F74FCD299

Q30411910-B5C957C0-AF29-4EEF-AEE2-CBFB070C3CBB

Q30411910-CBF0707A-66A9-4E2E-9846-57C2339EDF31

Q30411910-D101AB1F-8610-417E-B6A0-385456330085

Q30411910-F1642581-DB24-4998-A5D8-B450B1AEAE1C

P2860

Q30411910-1762D075-D25A-4CA3-B975-CF53EBECDFAD

Q30411910-1BC92C61-46D2-4C0D-9DD0-F3378C80D48A

Q30411910-3923DC7C-1675-4F28-BF59-DCAD9EC64317

Q30411910-3A462237-77FA-4135-9862-104F35EB8B58

Q30411910-48CDB2E2-8E39-4E59-8D36-3B5DA951DC6B

Q30411910-4A22CD01-1D00-469C-8D2C-2FC735A39E05

Q30411910-508BF2F5-D180-4DA5-8C17-DE1CB26AA1BE

Q30411910-57A6CCCC-9CFB-47B8-A5A1-40FFC0433F9C

Q30411910-5858C6EE-30DB-4A2E-B13A-1BC4AFC40AA7

Q30411910-5A5C8C40-6551-46D8-BE16-5B357D72B691

P304

Q30411910-A165D26D-5F18-429D-8A3C-88D7BE8ED9FC

P31

Q30411910-A6A66B02-9EB9-42A4-A308-B21CAD2B8034

P356

Q30411910-BD9B0E22-8ACF-424B-AF44-591201905EE2

P407

Q30411910-FE6395CE-D399-4BB3-B2D7-D50520FABD47

P433

Q30411910-73ED6D8F-9B4F-4DF0-AA7F-5B515B690B3B

P478

Q30411910-9C359F5A-100A-4973-8967-15B63382059A

P577

Q30411910-086E183D-0DED-449D-ACD5-9289B3024833

P698

Q30411910-E8EE2FA4-0B5D-4970-B8AB-ED01A2CF897C

P921

Q30411910-0C307029-B50E-4C06-979E-F07793390665

Q30411910-294B5F0A-5541-456E-B03D-69F18297904D

Q30411910-A6671F1E-D49F-42E3-825B-72F74F55B6F7

Q30411910-BA9CF6D5-AD05-4441-AD02-8B30653072CB

P932

Q30411910-771692B7-DC81-46A4-A6F8-7F862664621B

P356

J.YGYNO.2012.11.038

P1433

Gynecologic Oncology

P1476

Patient reported outcomes of a ...... necologic Oncology Group Study

@en

P2093

Benjamin E Greer

http://www.w3.org/2001/XMLSchema#string

Bradley J Monk

http://www.w3.org/2001/XMLSchema#string

Helen Q Huang

http://www.w3.org/2001/XMLSchema#string

Howard D Homesley

http://www.w3.org/2001/XMLSchema#string

Jeffrey Fowler

http://www.w3.org/2001/XMLSchema#string

Lari Wenzel

http://www.w3.org/2001/XMLSchema#string

Matthew Boente

http://www.w3.org/2001/XMLSchema#string

Robert A Burger

http://www.w3.org/2001/XMLSchema#string

Robert S Mannel

http://www.w3.org/2001/XMLSchema#string

Sharon X Liang

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2012

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group study.

The association between quality of life domains and overall survival in ovarian cancer patients during adjuvant chemotherapy: a Gynecologic Oncology Group Study

Validation of FACT/GOG-AD subscale for ovarian cancer-related abdominal discomfort: a Gynecologic Oncology Group study.

A phase 3 trial of bevacizumab in ovarian cancer.

Making sense of clinical trial data: is inverse probability of censoring weighted analysis the answer to crossover bias?

Methods to explain the clinical significance of health status measures.

Minimally important differences were estimated for six Patient-Reported Outcomes Measurement Information System-Cancer scales in advanced-stage cancer patients

P304

573-578

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.YGYNO.2012.11.038

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

128

http://www.w3.org/2001/XMLSchema#string

P577

2012-12-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23219660

http://www.w3.org/2001/XMLSchema#string

P921

P932

4099057

http://www.w3.org/2001/XMLSchema#string